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Introduction 
Peak inspiratory flow (PIF) has been shown to be associated with exacerbation severity in 
chronic obstructive pulmonary disease (COPD) and with subsequent hospital readmission. 
However, PIF is not routinely measured and thus rarely available in electronic health 
records. Finding strong proxy measures for PIF which are available from spirometry and 
routine patient care parameters, would be valuable in improving COPD management.  
Methods 
This was a retrospective observational study using data collected at Attikon hospital, Athens, 
Greece, in COPD patients during an unplanned hospitalisation for a COPD exacerbation. 
Spirometry was conducted using a portable PC-based spirometer (Easy on-PC). PIF was 
measured using In-Check device with 4 resistance settings simulating: Handihaler, Aerolizer, 
Diskus and Turbohaler devices.  
Univariable and multivariable linear regression models were used to investigate the 
association between PIF and other lung spirometry measures taken on the day of discharge, 
co-morbidities, and demographics.  
Results 
The study sample consisted of 47 COPD patients with PIF and spirometry data. The mean 
age was 71 years (SD 9.0) and 72% were male. Overall, 81% were classified as GOLD 
group (2016) D (high risk patients with more exacerbations), and 30% had at least 1 severe 
exacerbation in the past year. The most prevalent comorbidities were hypertension (70%) 
and cardiovascular disease (53%).  
In unadjusted analysis for Aerolizer and Diskus, FEV1 and % Predicted PEF were 
significantly associated with PIF. For turbohaler, PIF was also significantly associated with % 
predicted FVC, % predicted FEV1 and log(FEF25-75). However, all measures were weakly 
(R2<0.3) correlated with PIF (Table 1). In the final multivariate regression model for 
Aerolizer, FEV1 and Gastroesophageal reflux disease (GERD) were the factors associated 
with PIF. The final model for Diskus included FEV1, age, and Ischaemic Heart Disease (IHD), 
and for Turbohaler, FEV1 and % predicted PEF. However, R-squared values of the 
regression models for all 3 devices were weak (<0.4). Regression for Handihaler did not 
allow for adequate model fit, and thus was not further analysed. 
Conclusion 
All of the routine lung function measures were only weakly associated with PIF, despite 
statistical significance. While PIF measurement would be a valuable addition to standard of 
care in COPD management, it needs to be measured directly. 
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Table 1. Simple linear regression for association between spirometry measures and PIF 
  Simple linear regression 
In-Check setting Covariate Parameter estimate 
(95% CI) 
R-squared statistic 
Aerolizer FEV1 18.4 (2.6, 34.3)* 0.109 
FEV1/FVC 20.6 (-31.2, 72.5) 0.014 
% predicted FVC 0.40 (-0.091, 0.89) 0.056 
% predicted FEV1 0.29 (-0.11, 0.69) 0.045 
log(FEF25-75) 8.4 (-3.5, 20.3) 0.046 
% predicted PEF 0.47 (0.10, 0.84)* 0.133 
Diskus FEV1 19.9 (6.8, 33.0)* 0.172 
FEV1/FVC 23.7 (-20.5, 67.9) 0.025 
% predicted FVC 0.39 (-0.032, 0.81) 0.071 
% predicted FEV1 0.29 (-0.053, 0.63) 0.061 
log(FEF25-75) 7.4 (-2.6, 17.4) 0.050 
% predicted PEF 0.41 (0.091, 0.74)* 0.134 
Turbohaler FEV1 16.1 (7.2, 24.9)* 0.230 
FEV1/FVC 28.7 (-1.4, 58.8) 0.076 
% predicted FVC 0.39 (0.11, 0.67)* 0.151 
% predicted FEV1 0.35 (0.13, 0.58)* 0.180 
log(FEF25-75) 9.0 (2.4, 15.5)* 0.152 
% predicted PEF 0.43 (0.22, 0.63)* 0.294 
 
a) FEV1 = Forced Expiratory Flow in one second (litres); b) FVC = Forced Vital Capacity c) FEF25-75 = Forced Expiratory Flow; d) 
PEF = Peak Expiratory Flow *Statistically significant 
 
